The purpose of this comparison is to assess the efficacyof mutated KRAS ctDNA as a potential biomarker for anticipating chemotherapyresponse and tracking therapy in patients with advanced PC.27 The study sheds important light on the potentialutility of mutated KRAS ctDNA as a biomarker for assessing chemotherapyresponse and therapy monitoring in patients with advanced PC (Figure 3). This evidence concerns the gene KRAS and pachyonychia congenita.